Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars
Key Details
Gender
All
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
212
Start Date
2026-04
Completion Date
2026-12
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
LY4515100
Administered Orally
Placebo
Administered Orally
Locations (1)
JBR Clinical Research
Salt Lake City, Utah, United States